These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7699045)

  • 1. Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.
    Cormican MG; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):215-6. PubMed ID: 7699045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
    Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
    Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of levofloxacin against gram-positive bacteria.
    Montanari MP; Mingoia M; Marchetti F; Varaldo PE
    Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
    Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
    Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
    Dabernat H
    Int J Antimicrob Agents; 1999 Feb; 11(2):139-43. PubMed ID: 10221417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.
    Gesu GP; Marchetti F; Piccoli L; Cavallero A
    Antimicrob Agents Chemother; 2003 Feb; 47(2):816-9. PubMed ID: 12543701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
    Bajaksouzian S; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 May; 41(5):1073-6. PubMed ID: 9145872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.